参附注射液治疗感染性休克的临床疗效分析

2019-01-17 02:06曹健华
中外医疗 2019年32期
关键词:参附注射液感染性休克临床疗效

曹健华

[摘要] 目的 探討参附注射液治疗感染性休克的临床疗效。 方法 回顾性分析该院2017年11月—2019年2月收治的56例感染性休克患者的临床资料。患者随机分成治疗组和对照组,其中治疗组30例,除西医常规治疗外加用参附注射液,对照组26例仅用西医常规治疗,不加用参附注射液。观察并比较两组的平均动脉压(MAP)、中心静脉血氧饱和度(ScVO2)、心率(HR)、乳酸(Lac)、ICU住院时间、病死率以及多器官功能不全发生率。 结果 治疗24 h后治疗组与对照组平均动脉压(MAP)分别为(72±9.2)mmHg、(66±8.4) mmHg,差异有统计学意义(P=0.014<0.05);中心静脉血氧饱和度(ScVO2)分别为(86±14.3)%、(75±13.6)%,差异有统计学意义(P=0.020<0.05);心率(HR)分别为(105±10.2)次、(113±12.4)次,差异有统计学意义(P=0.011<0.05);乳酸(Lac)分别为(3.6±0.68)mmol/L、(4.2±0.81)mmol/L,差异有统计学意义(P=0.004<0.05)。治疗组与对照组ICU 住院时间分别为(8.3±2.7)d、(10.1±3.5)d,治疗组比对照组短,差异有统计学意义(P=0.034<0.05)。两组死亡率分别为20.0%、23.1%,差异无统计学意义(P=0.780>0.05)。两组多器官功能不全发生率分别为16.7%、42.3%,治疗组低于对照组,差异有统计学意义(P=0.034<0.05)。 结论 参附注射液可改善感染性休克患者的微循环,可以提高感染性休克的治疗效果,缩短住院时间,具有一定的临床应用价值。

[关键词] 参附注射液;感染性休克;临床疗效

[中图分类号] R278          [文献标识码] A          [文章编号] 1674-0742(2019)11(b)-0121-03

[Abstract] Objective To investigate the clinical efficacy of Shenfu injection in the treatment of septic shock. Methods The clinical data of 56 patients with septic shock admitted to the hospital from November 2017 to February 2019 were retrospectively analyzed. The patients were randomly divided into the treatment group and the control group, including 30 patients in the treatment group, except for the conventional treatment of western medicine plus Shenfu injection, and 26 patients in the control group were treated with only Western medicine, and Shenfu injection was not used. Mean arterial pressure (MAP), central venous oxygen saturation (ScVO2), heart rate (HR), lactic acid (Lac), ICU hospitalization, mortality, and multiple organ dysfunction were observed and compared between the two groups. Results After 24 hours of treatment, the mean arterial pressure (MAP) of the treatment group and the control group were(72±9.2)mmHg and( 66±8.4 )mmHg, respectively. The difference was statistically significant (P=0.014<0.05); central venous oxygen saturation (ScVO2) was (86±14.3)% and (75±13.6)%, respectively, with statistically significant differences (P=0.020<0.05). Heart rate (HR) was (105±10.2 )times and (113±12.4) times, respectively, and the difference was statistically significant (P=0.011<0.05); Lac was (3.6±0.68)mmol/L and (4.2±0.81)mmol/L, respectively, with statistically significant differences (P=0.004<0.05). The hospital stay in the ICU of the treatment group and the control group were (8.3±2.7)d and (10.1±3.5)d, respectively. The treatment group was shorter than the control group, and the difference was statistically significant (P=0.034<0.05). The mortality rate of the two groups was 20.0% and 23.1%, respectively, and the difference was not statistically significant (P=0.780>0.05). The incidence of multiple organ dysfunction in the two groups was 16.7% and 42.3%, respectively. The treatment group was lower than the control group, and the difference was statistically significant (P=0.034<0.05). Conclusion Shenfu injection can improve the microcirculation of patients with septic shock, improve the therapeutic effect of septic shock, shorten the hospital stay, and have certain clinical application value.

猜你喜欢
参附注射液感染性休克临床疗效
被动抬腿试验评价感染性休克患者容量反应性的意义探析
每搏量变异度监测指导感染性休克术中容量治疗的应用价值
乳酸清除率对感染性休克患者预后的预测价值
枸橼酸咖啡因治疗早产儿原发性呼吸暂停临床分析
微创手术治疗胃溃疡42例临床分析
研究腹腔镜在早期卵巢癌分期手术中的临床应用
早期应用前列地尔治疗急性脑梗死临床疗效观察
参附注射液治疗难治性脓毒血症并休克的临床观察
参附注射液外科临床用药特点分析